Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Abstract The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a
meeting to establish evidence-based recommendations for using tests to diagnose …

The substantial decline in the Pneumocystis jirovecii pneumonia (PCP) incidence in HIV-
infected patients after the introduction of antiretroviral therapy (ART) in resource-rich settings …

P neumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with
cancer‐related immunosuppression. There are well‐defined patients who are at risk of PJP …

Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or
“fungerp” that inhibits biosynthesis of β-(1, 3)-D-glucan in the fungal cell wall, a mechanism …

Pulmonary complications in CTD are common and can involve the interstitium, airways,
pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from …

Background Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening opportunistic
infection in immunocompromised hosts. The diagnosis can be challenging, often requiring …

Ibrutinib is not known to confer risk for Pneumocystis jirovecii pneumonia (PCP). We
observed 5 cases of PCP in 96 patients receiving single-agent ibrutinib, including 4 …

Pneumocystis, a unique atypical fungus with an elusive lifestyle, has had an important
medical history. It came to prominence as an opportunistic pathogen that not only can cause …

Pneumocystis jirovecii is the only fungus of its kind to be pathogenic in humans. It is
primarily responsible for pneumonia (PJP). The key to understanding immune defences has …